Market Overview:
The global biologic medication in COVID-19 market is expected to register a CAGR of XX% during the forecast period 2018-2030. The growth of this market can be attributed to the increasing incidence of COVID-19, rising demand for biologic medications for the treatment of COVID-19, and technological advancements in the field of biologics. Based on type, the global biologic medication in COVID-19 market is segmented into neutralizing antibodies and antiinflammatory drugs. The antiinflammatory drugs segment is expected to register a higher CAGR during the forecast period owing to its growing demand for treating various respiratory diseases such as asthma, COPD, and bronchitis. Based on application, the global biologic medication in COVID-19 market is segmented into COVID-19, influenza, malaria, and others (including tuberculosis and HIV/AIDS). The COVDI - 19 segment is estimated to account for a major share of this market during the forecast period owing to its high prevalence across different geographies. However; other applications are also projected to witness significant growth overthe next few years dueto increasing awareness about these diseasesand availabilityof effective treatments.
Product Definition:
A biologic medication is a drug that is derived from natural sources, such as animals or plants. These medications are often used to treat chronic conditions, such as arthritis or diabetes. Biologic medications can also be used to treat serious illnesses, such as cancer or HIV/AIDS.
Neutralizing Antibodies:
Neutralizing antibodies are the ones that bind to an antigen and neutralize its biological activity. Antibodies are proteins made by B cells and T cells in response to an antigen (a foreign substance). The most common antigens are bacterial toxins, such as tetanus, diphtheria, and botulism; viral particles such as HIV-1 & -2; tumor cell wall peptides; and chemical compounds such as warfarin.
Anti-inflammatory Drugs:
Anti-inflammatory drugs are used in biologic medication for the treatment of COVID-19. The anti-inflammatory drugs can be segmented into two types: first, those that act directly on the immune system; and second, those that indirectly affect the immune system by changing other biological processes. Direct anti-inflammatories block NO or prostaglandins (prostacyclin), which causes pain relief by reducing inflammation.
Application Insights:
Based on application, the global market is segmented into COVID-19, influenza, malaria, and others. Among these applications, COVID-19 held the largest share in 2017 owing to its high prevalence and rapid progression in unresponsive clinical settings. Moreover, this disease has a significant impact on both developed as well as developing countries due to its high mortality rate which drives demand for effective treatment options.
The growing usage of biologics for treating other infectious diseases such as HIV or tuberculosis will drive growth over the forecast period. In addition to this factor other factors such as increasing R&D investments by various companies are expected to boost product demand over the forecast period. For instance; in September 2016; Pfizer Inc., one of America's largest pharmaceutical companies announced about an investment of USD 120 million for discovering & developing novel medicines that would help treat more than 40 million people living with HIV/AIDS around the world [3].
Regional Analysis:
North America dominated the global market in 2018 owing to favorable government initiatives and increasing COVID-19 positive cases. The region is anticipated to maintain its dominance over the forecast period due to factors such as high disposable income, advanced healthcare infrastructure, and rising awareness among people about early diagnosis of diseases. Asia Pacific is expected to grow at a lucrative rate during the forecast period due to various factors such as improving healthcare facilities & infrastructure, growing economy & population, increase in foreign tourist visits every year along with rise in medical tourism for treatment of COVID-19 infection.
Growth Factors:
- Increased demand for biologic medications due to the COVID-19 pandemic.
- Government and insurance company support for increased use of biologic medications.
- Research and development of new biologic medications to address the needs of patients with COVID-19.
- Availability of biosimilars for some biologic medications, which will help to keep costs down for patients and healthcare providers.
- Continued education and awareness about the benefits of using biologic medications in appropriate patients with COVID-19
Scope Of The Report
Report Attributes
Report Details
Report Title
Biologic Medication in COVID-19 Market Research Report
By Type
Neutralizing Antibodies, Anti-inflammatory Drugs
By Application
COVID-19, Influenza, Malaria, Others
By Companies
Roche, Sanofi, Novartis, Merck, Bayer, Shutaishen, Biogen, Regeneron Pharmaceuticals, Vir Biotech, Junshi Biosciences, Anke Biotechnology, OncoImmune
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
184
Number of Tables & Figures
129
Customization Available
Yes, the report can be customized as per your need.
Global Biologic Medication in COVID-19 Market Report Segments:
The global Biologic Medication in COVID-19 market is segmented on the basis of:
Types
Neutralizing Antibodies, Anti-inflammatory Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
COVID-19, Influenza, Malaria, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Sanofi
- Novartis
- Merck
- Bayer
- Shutaishen
- Biogen
- Regeneron Pharmaceuticals
- Vir Biotech
- Junshi Biosciences
- Anke Biotechnology
- OncoImmune
Highlights of The Biologic Medication in COVID-19 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Neutralizing Antibodies
- Anti-inflammatory Drugs
- By Application:
- COVID-19
- Influenza
- Malaria
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biologic Medication in COVID-19 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Biologic medications are medications that use living organisms to treat a disease. These medications can be administered through injection, inhalation, or ingestion.
Some of the major companies in the biologic medication in covid-19 market are Roche, Sanofi, Novartis, Merck, Bayer, Shutaishen, Biogen, Regeneron Pharmaceuticals, Vir Biotech, Junshi Biosciences, Anke Biotechnology, OncoImmune.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Biologic Medication in COVID-19 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Biologic Medication in COVID-19 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Biologic Medication in COVID-19 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Biologic Medication in COVID-19 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Biologic Medication in COVID-19 Market Size & Forecast, 2018-2028
4.5.1 Biologic Medication in COVID-19 Market Size and Y-o-Y Growth
4.5.2 Biologic Medication in COVID-19 Market Absolute $ Opportunity
Chapter 5 Global Biologic Medication in COVID-19 Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Biologic Medication in COVID-19 Market Size Forecast by Type
5.2.1 Neutralizing Antibodies
5.2.2 Anti-inflammatory Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Biologic Medication in COVID-19 Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Biologic Medication in COVID-19 Market Size Forecast by Applications
6.2.1 COVID-19
6.2.2 Influenza
6.2.3 Malaria
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Biologic Medication in COVID-19 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Biologic Medication in COVID-19 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Biologic Medication in COVID-19 Analysis and Forecast
9.1 Introduction
9.2 North America Biologic Medication in COVID-19 Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Biologic Medication in COVID-19 Market Size Forecast by Type
9.6.1 Neutralizing Antibodies
9.6.2 Anti-inflammatory Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Biologic Medication in COVID-19 Market Size Forecast by Applications
9.10.1 COVID-19
9.10.2 Influenza
9.10.3 Malaria
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Biologic Medication in COVID-19 Analysis and Forecast
10.1 Introduction
10.2 Europe Biologic Medication in COVID-19 Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Biologic Medication in COVID-19 Market Size Forecast by Type
10.6.1 Neutralizing Antibodies
10.6.2 Anti-inflammatory Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Biologic Medication in COVID-19 Market Size Forecast by Applications
10.10.1 COVID-19
10.10.2 Influenza
10.10.3 Malaria
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Biologic Medication in COVID-19 Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Biologic Medication in COVID-19 Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Biologic Medication in COVID-19 Market Size Forecast by Type
11.6.1 Neutralizing Antibodies
11.6.2 Anti-inflammatory Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Biologic Medication in COVID-19 Market Size Forecast by Applications
11.10.1 COVID-19
11.10.2 Influenza
11.10.3 Malaria
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Biologic Medication in COVID-19 Analysis and Forecast
12.1 Introduction
12.2 Latin America Biologic Medication in COVID-19 Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Biologic Medication in COVID-19 Market Size Forecast by Type
12.6.1 Neutralizing Antibodies
12.6.2 Anti-inflammatory Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Biologic Medication in COVID-19 Market Size Forecast by Applications
12.10.1 COVID-19
12.10.2 Influenza
12.10.3 Malaria
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Biologic Medication in COVID-19 Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Biologic Medication in COVID-19 Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Biologic Medication in COVID-19 Market Size Forecast by Type
13.6.1 Neutralizing Antibodies
13.6.2 Anti-inflammatory Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Biologic Medication in COVID-19 Market Size Forecast by Applications
13.10.1 COVID-19
13.10.2 Influenza
13.10.3 Malaria
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Biologic Medication in COVID-19 Market: Competitive Dashboard
14.2 Global Biologic Medication in COVID-19 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Sanofi
14.3.3 Novartis
14.3.4 Merck
14.3.5 Bayer
14.3.6 Shutaishen
14.3.7 Biogen
14.3.8 Regeneron Pharmaceuticals
14.3.9 Vir Biotech
14.3.10 Junshi Biosciences
14.3.11 Anke Biotechnology
14.3.12 OncoImmune
